Merck's Keytruda and Bristol-Myers Squibb's Opdivo may be two of the most watched drugs in pharma right now. That's not only because both are breakthrough immunotherapy cancer treatments, but also because both are racing to win additional indications. And when it comes to marketing, each one is playing its advantage.
Industry watchers expect biosimilars for AbbVie's Humira to be the most successful copycat biologics launched in the U.S. and Europe, and that's something Merck and Samsung are trying to get in on.
Partners Merck and Samsung Bioepis cleared late-stage trials with their knockoff of Humira, the world's top-selling medicine, setting the stage for global regulatory applications as the reference treatment comes off patent.
South Korea-based Samsung Bioepis is ready to head to regulators with a biosimilar of AbbVie's Humira (adalimumab) after successfully completing Phase III trials on its candidate now dubbed SB5. The company says SB5 met its primary endpoint and showed equivalence to the original version in patients with moderate to severe rheumatoid arthritis who did not respond to methotrexate therapy.
Merck is bowing out of the hectic late-stage scramble to be the first to market with a CGRP migraine drug, handing over its portfolio and two experimental drugs in the pipeline to Allergan for $250 million in cash.
Fresh off a landmark $1 billion deal to buy into Juno's immuno-oncology pipeline, fast-growing Celgene has inked another contract to buy up Merck's sprawling old campus in Summit, NJ.
Multinational drug firms in Australia faced a string of barbs in hearings held by a Senate panel into transfer pricing that included a reference to a fictitious German World War II prison camp guard.
Merck posted another batch of promising Phase III data for Emend, its antivomiting drug for chemo patients. The pharma giant noted that in the study its NK1 receptor agonist scored a statistically significant complete response rate among patients getting a moderately emetogenic (or vomit-inducing) chemotherapy. Merck will now look to broaden its label for the drug for chemotherapy-induced nausea and vomiting (CINV) as it squares off against prospective competitors.
Wading into what has become an "argy-bargy" political issue, Merck CEO Ken Frazier gave his two cents on why Australians miss out on new drugs.
The top 10 companies producing diabetes meds raked in about $62 billion in global sales in 2014, up 5.1% from the previous year, according to a report from data analytics firm GlobalData. Companies such as Novo Nordisk, Sanofi and Merck lead the pack, posting solid gains for their products as they compete for a piece of a rapidly growing market.